Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Reconciliation of Cash, Cash Equivalents, and Restricted Cash

A reconciliation of cash, cash equivalents, and restricted cash reported in the accompanying condensed consolidated balance sheets to the amount reported within the accompanying condensed consolidated statements of cash flows was as follows (in thousands):


		June 30, 2026				December 31, 2025
Cash and cash equivalents		$	255,271			$	122,518
Restricted cash			3,107				3,114
Total cash, cash equivalents, and restricted cash as reported within our condensed consolidated statement of cash flows		$	258,378			$	125,632

Schedule of Accounts Receivable, Net

Accounts receivable, net was as follows (in thousands):


		June 30, 2026				December 31, 2025
Accounts receivable, net:
Net product receivables		$	21,517			$	—
Collaboration receivables			2,915				17,764
Total accounts receivable, net		$	24,432			$	17,764

Schedule of Inventories

Inventories were as follows (in thousands):


		June 30, 2026				December 31, 2025
Inventories:
Raw materials		$	5,535			$	—
Work in process			994				—
Finished goods			380				—
Total inventories		$	6,909			$	—

Summary of Accrued Liabilities

Accrued liabilities were as follows (in thousands):


		June 30, 2026				December 31, 2025
Accrued liabilities:
Clinical and preclinical costs		$	21,166			$	24,561
Compensation related			34,338				45,150
Other accrued expenses			21,358				13,567
Total accrued liabilities		$	76,862			$	83,278